Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01636206 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 332
- Enrollment target
NCT01636206 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 332 participants.
The verdict
NCT01636206, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 332 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.
Interventions
- DRUG Placebo
- DRUG Lifitegrast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2012-10-16 |
| Est. Completion | 2014-03-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01636206
The ClinicalTrials.gov registry entry for NCT01636206 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01636206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01636206 about?
NCT01636206 is a clinical study titled "Safety Study of Lifitegrast to Treat Dry Eye". The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.
What is the current status of trial NCT01636206?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2012-10-16. Estimated completion is 2014-03-03.
What interventions are being tested in trial NCT01636206?
The interventions under investigation include: Placebo (DRUG), Lifitegrast (DRUG).
Who is sponsoring clinical trial NCT01636206?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.